MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Short and long-term cental action of botulinum neurotoxin treatment in laryngeal dystonia

    L. O'Flynn, K. Simonyan (Boston, USA)

    Objective: To investigate short- and long-term central effects of BoNT treatment on brain function in patients with laryngeal dystonia (LD). Background: LD is an isolated…
  • 2022 International Congress

    Effect of rehabilitation interventions on freezing of gait in people with Parkinson’s disease: a systematic review and meta-analyses

    L. Goh, C. Canning, J. Song, L. Clemson, N. Allen (Camperdown, Australia)

    Objective: To summarize the effects of rehabilitation interventions to reduce freezing of gait (FOG) in people with Parkinson’s disease (PwPD). Background: FOG is a debilitating…
  • 2022 International Congress

    Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease

    I. Frouni, W. Kang, D. Bédard, L. Desbiens, C. Kwan, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…
  • 2022 International Congress

    Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg on the pharmacokinetics (PK) of levodopa (LD) in different LD/carbidopa (LD/CD)…
  • 2022 International Congress

    Relationship between gait speed and functional measurements in Parkinson’s disease

    D. Iucksch, B. Yamaguchi, L. Araujo, V. Israel (CURITIBA, Brazil)

    Objective: The present study aims to relate gait speed in Parkinson's disease (PD) with functional measures of muscle strength, balance and physical capacity. Background: PD…
  • 2022 International Congress

    STN-DBS Targeting SNr Modulates Sleep in Parkinson’s Disease: A Proof-of-Concept Study

    HL. Yu, LX. Guan, YN. Sui, F. Ba, LM. Li (Beijing, China)

    Objective: To explore how subthalamic deep brain stimulation (STN-DBS) targeting substantia nigra pars reticulata (SNr) can modulate sleep in Parkinson’s disease (PD) patients with electrophysiologic…
  • 2022 International Congress

    Pseudodystonia due to Palmaris Brevis Syndrome: Case Report

    D-Y. Liou, A. Alamoudi, D. Preston, C. Kilbane (Cleveland, USA)

    Objective: We describe a case of pseudodystonia caused by palmaris brevis syndrome. Background: Palmaris brevis (PB) syndrome is a pseudodystonia characterized by spontaneous, involuntary, nonpainful…
  • 2022 International Congress

    Mosaicism for somatic SNCA copy number variants in multiple system atrophy is related to pathological subtype and presence of α-synuclein inclusions

    C. Proukakis, M. Garcia-Segura, D. Perez-Rodriguez, Z. Jaunmuktane (London, United Kingdom)

    Objective: To investigate the correlation of somatic copy number variants (CNVs) of the alpha-synuclein gene (SNCA) in multiple system atrophy (MSA) with disease subtype, and…
  • 2022 International Congress

    Assessment of non-motor symptoms of Parkinson’s disease in the long-term follow-up after the cell therapy

    V. Chyzhyk, A. Boika, V. Ponomarev (Minsk, Belarus)

    Objective: To evaluate the results of the introduction of MSCs on the non-motor symptoms in patients with PD within 12 months after the cell therapy.…
  • 2022 International Congress

    A qualitative study exploring the treatment burden and capacity of people with Parkinson’s and their caregivers

    QY. Tan, H. Roberts, S. Fraser, K. Ibrahim (Southampton, United Kingdom)

    Objective: To explore experiences of treatment burden and capacity in Parkinson’s and identify potentially modifiable factors that can improve this Background: Treatment burden, the workload…
  • « Previous Page
  • 1
  • …
  • 86
  • 87
  • 88
  • 89
  • 90
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley